Estrogens and lipid metabolism

Current Opinion in Endocrinology and Diabetes

Volumn 5, Issue 4, 1998, Pages 261-267

  Westerveld, H E ^a   Erkelens, D W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHYLOMICRON; ESTROGEN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; ESTROGEN ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; RECEPTOR UPREGULATION; REVIEW;

EID: 0031741987     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199811000-00005     Document Type: Review

References (63)

1. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins [see comments]. N Engl J Med 1991, 325:1196-1204.
2. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB Jr, Levy RI: The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983, 57:262-267.
3. Walsh BW, Sacks FM: Effects of low dose oral contraceptives on very low-density and low-density lipoprotein metabolism. J Clin Invest 1993, 91:2126-2132.
4. Wolfe BM, Huff MW: Effects of continuous low-dosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women. Metabolism 1995, 44:410-417. [Published erratum appears in Metabolism 1995, 44:963]
5. Wolfe BM, Huff MW: Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women. J Clin Invest 1989, 83:40-45.
6. Campos H, Walsh BW, Judge H, Sacks FM: Effect of estrogen on very low-density lipoprotein and low-density lipoprotein subclass metabolism in postmenopausal women [see comments]. J Clin Endocrinol Metab 1997, 82:3955-3963. In a kinetic study using stable isotope labeling of apo B100, the effects of 17β-estradiol, 2 mg, on metabolism of subclasses of VLDL and LDL are described. The fractional catabolic rate of all apo B100 containing particles was increased, including small, dense LDL. The study is an extension of the study by Walsh et al. (N Engl J Med 1991, 325:1196-1204).
7. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PW, Schaefer EJ: Effect of gender, age, and lipid status on low-density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis 1987, 7:483-490.
8. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR: Menopause and risk factors for coronary heart disease [see comments]. N Engl J Med 1989, 321:641-646.
9. Li Z, McNamara JR, Fruchart JC, et al.: Effects of gender and menopausal status of plasma lipoprotein subspecies and particle sizes. J Lipid Res 1996, 37:1886-1896.
10. Westerveld HT, Kock LA, van Rijn HJ, Erkelens DW, de Bruin TW: 17 beta-Estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995, 80:249-253.
11. Applebaum Bowden D, McLean P, Steinmetz A, et al.: Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration of postmenopausal women. J Lipid Res 1989, 30:1895-1906.
12. Brinton EA: Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates on lipoprotein A-1 and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 1996, 16:431-440.
13. Havel RJ: Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994, 5:102-109.
14. Kannel WB, Castelli WP, Gordon T, McNamara PM: Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham study. Ann Intern Med 1971, 74:1-12.
15. Meyer E, Westerveld HT, de Ruyter Meijstek FC, et al.: Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996, 124:221-235.
16. Uiterwaal CS, Grobbee DE, Witteman JC, et al.: Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis [see comments]. Ann Intern Med 1994, 121:576-583.
17. Karpe F, Steiner G, Uffelman K, Olivercrona T, Hamsten A: Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106:83-97.
18. Bass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993, 153:2209-2216.
19. Kannel WB: Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987, 114:413-419.
20. Barrett Connor E, Bush TL: Estrogen and coronary heart disease in women [see comments]. JAMA 1991, 265:1861-1867.
21. Cohn JS, Giroux LM, Fortin U, Davignon J: Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status, and ApoE phenotype. Arterioscler Thromb Vasc Biol 1997, 17:2630-2637. The presence of double preβ lipoproteinemia (DPBL), ie, both preβ-VLDL (normal VLDL) and slow preα-VLDL (remnants) are a characteristic of remnant accumulation in hyperlipidemic subjects. Men, postmenopausal women, and carriers of the apoE2 allele had a higher prevalence of DPBL.
22. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ: Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988, 29:469-479.
23. Jackle S, Rinninger F, Greeve J, Greten H, Windler E: Regulation of the hepatic removal of chylomicron remnants and beta-very low density lipoproteins in the rat. J Lipid Res 1992, 33:419-429.
24. Demacker PN, Staels B, Stalenhoef AF, Auwerx J: Increased removal of beta-very low-density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1991, 11:1652-1659.
25. Berr F, Eckel RH, Kern F Jr: Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. J Lipid Res 1986, 27:645-651.
26. Gleeson J, Dukes CS, Elstad, NL, Chan IF, Wilson DE: Effects of estrogen/progestin agents on plasma retinoids and chylomicron remnant metabolism. Contraception 1987, 35:69-78.
27. Stuyt PM, Demacker PN, van't Laar A: A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia. Horm Metab Res 1986, 18:607-610.
28. Kushwaha RS, Hazzard WR, Gagne C, Chait A, Albers JJ: Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen. Ann Intern Med 1977, 87:517-525.
29. Everson GT, McKinley C, Kern F Jr: Mechanisms of gallstone formation in women: effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991, 87:237-246.
30. Kern F Jr, Everson GT: Contraceptive steroids increase cholesterol in bile: mechanisms of action. J Lipid Res 1987, 28:828-839.
31. Eriksson M, Angelin B, Henriksson P, Ericsson S, Vitols S, Berglund L: Metabolism of lipoprotein remnants in humans: studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arterioscler Thromb 1991, 11:827-837.
32. Karpe F, Humphreys SM, Samra JS, Summers LK, Frayn KN: Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans. Lancet 1997, 350:1047-1059.
33. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL: The estradiol-stimulated lipoprotein receptor of rat liver: a binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 1980, 255:10464-10471.
34. Ma PT, Yamamoto T, Goldstein JL, Brown MS: Increased mRNA for low-density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol. Proc Natl Acad Sci U S A 1986, 83:792-796.
35. Parini P, Angelin B, Rudling M: Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler Thromb Vas ciol 1997, 17:1800-1805. An essential role for the estrogen-receptor in the estrogen induced upregulation of the LDL receptor is demonstrated by comparing the effect of estrogens with anti-estrogens on LDL-receptor mRNA and protein.
36. Matsubara Y, Murata M, Kawano K, et al.: Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol 1997, 17:3006-3012.
37. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ: Differences in low-density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1998, 67:30-35.
38. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM: Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993, 42:1153-1158.
39. Farish E, Spowart K, Barnes JF, et al.: Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis 1996, 126:77-84.
40. Griffin B, Parish E, Walsh D, et al.: Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause. Clin Endocrinol (Oxf) 1993, 39:463-468.
41. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM: Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 1996, 16:794-801.
42. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
43. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women [see comments]. JAMA 1996, 276:875-881.
44. Espeland MA, Marcovina SM, Miller V, et al.: Effect of postmenopausal hormone therapy on lipoprotein(a) concentration: Postmenopausal Estrogen/Progestin Interventions Investigators. Circulation 1998, 97:979-986. In an extension of the PEPI trial, long-term (3-year) CEE, 0.625 mg, decreased lipoprotein(a). This effect was not influenced by the addition of a progestin.
45. Seed M, Crook D: Post-menopausal hormone replacement therapy: coronary heart disease and plasma lipoproteins. Curr Opin Lipidol 1994, 5:48-58.
46. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial [see comments]. JAMA 1995, 273:199-208.
47. Westerveld HT, Meijer E, Erkelens DW, de Bruin TW: Postprandial reduction in high-density lipoprotein cholesterol concentrations in postmenopausal women: improvement by 17β-estradiol. Metabolism 1996, 45:827-832.
48. Walsh BW, Li H, Sacks FM: Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high-density lipoprotein metabolism. J Lipid Res 1994, 35:2083-2093.
49. Grodstein F, Stampfer MJ, Colditz GA, et al.: Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769-1775.
50. Sattar N, Jaap AJ, MacCuish AC: Hormone replacement therapy and cardiovascular risk in post-menopausal women with NIDDM. Diabet Med 1996, 13:782-788.
51. Chait A, Brunzell JD: Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism 1983, 32:209-214.
52. Godsland IF, Crook D: Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol 1994, 170:1528-1536.
53. Brussaard HE, Gevers Leuven JA, Frohlich M, Kluft C, Krans HM: Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997, 40:843-849. 17β-Estradiol improved fasting plasma lipids, apolipoproteins, glycemic control, and hepatic insulin sensitivity in postmenopausal women with NIDDM.
54. Andersson B, Mattsson LA, Hahn L, et al.: Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:638-643. 17β-Estradiol, 2 mg, improved fasting plasma lipids and glycemi control in hyperandrogenic postmenopausal women with NIDDM.
55. Robinson JG, Folsom AR, Nabulsi AA, Watson R, Brancati FL, Cai J: Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? Diabetes Care 1996, 19:480-485.
56. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89:1333-1445.
57. Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB: A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholeterolemia in postmenopausal women. Arch Intern Med 1997, 157:1186-1192. The effects of CEE, 0.625 mg; pravastatin, 20 mg; and a combination of both on plasma lipids are compared in hypercholesterolemic postmenopausal women.
58. Darling GM, Jones JA, McCloud PI, Davis SR: Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997, 337:595-601. The effects of high-dose continuous combined HRT (CEE, 1.25 mg, plus MPA, 5 mg) and low-dose simvastatin (10 mg) on plasma lipids are compared in hypercholesterolemic postmenopausal women.
59. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies. Lancet 1997, 350:1047-1059.
60. Delmas PD, Bjamason NH, Mitlak BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [see comments]. N Engl J Med 1997, 337:1641-1647. Raloxifene decreased LDL cholesterol without significant effects on triglycerides or HDL cholesterol. Bone mineral density was increased. No endometrium proliferation was observed.
61. Walsh BW, Kuller LH, Wild RA, Paul S, Shah A, Anderson PW: The effect of raloxifene on markers of cardiovascular risk in healthy postmenopausal women [abstract] Atherosclerosis 1997, 134:182.
62. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR: Androgen receptor mediated antagonism of estrogen dependent low-density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 1997, 138:3779-3786.
63. Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettmen TA: Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer [see comments]. J Clin Oncol 1995, 13:2900-2905.